Nandrolone decanoate and intranasal calcitonin as therapy in established osteoporosis

Osteoporosis International

Volumn 7, Issue 1, 1997, Pages 29-35

  Flicker, L ^a,c   Hopper, J L ^a   Larkins, R G ^a   Lichtenstein, M ^b   Buirski, G ^a   Wark, J D ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b ROYAL MELBOURNE HOSPITAL   (Australia)

^c NATIONAL AGEING RESEARCH INSTITUTE   (Australia)

Author keywords

Bone density; Calcitonin; Females; Nandrolone decanoate

Indexed keywords

ANABOLIC AGENT; NANDROLONE DECANOATE; SALCATONIN;

ADULT; AGED; ARTICLE; BONE DENSITY; BONE MASS; BONE MINERAL; CALCIUM INTAKE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET SUPPLEMENTATION; DOUBLE BLIND PROCEDURE; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FEMUR; FOREARM; HOARSENESS; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; INTRANASAL DRUG ADMINISTRATION; LEG EDEMA; LUMBAR SPINE; MAJOR CLINICAL STUDY; OSTEOPENIA; OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TRABECULAR BONE;

ADMINISTRATION, INTRANASAL; AGED; AGED, 80 AND OVER; ANABOLIC AGENTS; BONE DENSITY; CALCITONIN; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MIDDLE AGED; NANDROLONE; OSTEOPOROSIS, POSTMENOPAUSAL; PROSPECTIVE STUDIES;

EID: 0031040525     PISSN: 0937941X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01623456     Document Type: Article

References (27)

1. Lindsay R, Tohme JF. Estrogen treatment of patients with established postmenopausal osteoporosis. Obstet Gyrsecol 1990;76:290-5.
2. Christiansen C, Riis BJ. 17β-Estradiol and continuous norethisterone: a unique treatment for established osteoporosis in elderly women J Clin Endocrinol Metab 1990;71:836-41.
3. Reid IR, Ames RW, Evans MC, Gamble GD, Sharpe SJ. Effect of calcium supplementation on bone loss in postmenopausal women. N Engl J Med 1993;328:460-4.
4. Riggs BL, Hodgson SF, O'Fallon WM, et al. Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J Med 1990;322:802-9.
5. Watts NB, Harris ST, Genant HK, et al. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 1990;323:73-9.
6. Tillyard MW, Spears GF, Thomson J, Dovey S. Treatment of postmenopausal osteoporosis with calcitriol or calcium. N Engl J Med 1992;326:357-62.
7. Kopera H. The history of anabolic steroids and a review of clinical experience with anabolic steroids. Acta Endocrinol 1985;110 (Suppl 271):11-8.
8. 3 or intermittent calcium infusion therapy on bone mineral content, bone remodelling and fracture rate in symptomatic osteoporosis: a double-blind controlled study. Bone Miner 1986;1:347-57.
9. 3, or intermittent calcium infusions. Maturitas 1986;8:281-9.
10. Need AG, Morris HA, Hartley TF, Horowitz M, Nordin BEC. Effects of nandrolone decanoate on forearm mineral density and calcium metabolism in osteoporotic postmenopausal women. Calcif Tissue Int 1987;41:7-10.
11. Johansen JS, Hassager C, Podenphant J, et al Treatment of postmenopausal osteoporosis: is the anabolic steroid nandrolone decanoate a candidate? Bone Miner 1989;6:77-86.
12. Need AG, Horowitz M, Walker CJ, Chatterton BE, Chapman IC, Nordin BEC. Cross-over study of fat-corrected forearm mineral content during nandrolone decanoate therapy for osteoporosis. Bone 1989;10:3-6.
13. Gennari C, Agnus-Dei D, Gannelli S, Nardi P. Effects of nandrolone decanoate therapy on bone mass and calcium metabolism in women with established postmenopausal osteoporosis: a double-blind placebo-controlled study. Maturitas 1989;11:187-97.
14. Passen M, Pedrazzoni M, Pioli G, Battarini L, Ruys AH, Cortenraad MG. Effects of nandrolone decanoate on bone mass in established osteoporosis. Maturitas 1993;17:211-19.
15. Lyritis GP, Androulakis C, Magiasis B, Charalambaki Z, Tsakalakos N. Effect of nandrolone decanoate and 1α-hydroxycalciferol on patients with vertebral osteoporotic collapse: a double-blind clinical trial. Bone Miner 1994;27:209-17.
16. Erdtsieck RJ, Pols HAP, Kuijk CV, Birkenhager-Frenkel DH, Zeelenberg J, Kooy PPM, et al. Course of bone mass during and after hormonal replacement therapy with and without addition of nandrolone decanoate. J Bone Miner Res 1994;9:277-83.
17. Gruber HE, Ivey JL, Baylink DJ, Matthews M, Nelp WB, Sisom K, Chesnut CH III. Long-term calcitonin therapy in postmenopausal osteoporosis. Metabolism 1984; 33:295-303.
18. Reginster JY, Albert A, Lecart MP, Lambellin P, Denis D, Deroisy R, Fontane MA, Franchimont P. One year controlled randomised trial of prevention of early postmenopausal bone loss by intranasal calcitonin. Lancet 1987;2:1481-3.
19. Overgaard K, Riis BJ, Christiansen C, Hansen MA. Effect of salcatonin given intranasally on early postmenopausal bone loss. BMJ 1989;299:477-9.
20. Overgaard K, Riis BJ, Christiansen C, Podenphant J, Johansen JS Nasal calcitonin for treatment of established osteoporosis. Clin Endocrinol 1989;30:435-42.
21. Overgaard K, Hansen MA, Jensen SB, Christiansen C. Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study. BMJ 1992;305:556-61.
22. Szucs J, Horvath C, Kollin E, Szathmari M, Hollo I. Three-year calcitonin combination therapy for postmenopausal osteoporosis with crush fractures of the spine. Calcif Tissue Int 1992;50:7-10
23. Reinbold WD, Genant HK, Reiser JJ, Harris ST, Ettinger B. Bone mineral content in early-postmenopausal and postmenopausal osteoporotic women. comparison of measurement methods. Radiology 1986;160:469-78.
24. Flicker L, Green R, Kaymakci B, Lichtenstein M, Buirski G, Wark JD. Do Australian women have greater spinal bone density than North American women? Osteoporosis Int 1995;5:63-5.
25. McCullagh P, Neider JA, Generalized linear models. 2nd ed. Monographs on statistics and applied probability no. 37. London: Chapman & Hall, 1989.
26. Thamsborg G, Jensen JE, Kollerup G, Hauge EM, Melsen F, Sorensen OH. Effect of nasal salmon calcitonin on bone remodelling and bone mass in postmenopausal osteoporosis. Bone 1996;18:207-12.
27. Doers T, Pienkowski D, Faugere MC, Malluche HH. Calcitonin reduces bone mineral density and torsional mechanical properties of canine long bones. J Bone Miner Res 1994;9:S268.